{"prompt": "['Appendix 2', 'Schedule of Pharmacokinetic, Immunogenicity, and', 'Biomarker Samples (cont.)', 'd.', 'Serum and plasma EDTA samples for bone markers must be collected after fasting (no food or', 'drink other than water for at least 8 hours prior to the blood draw). Ideally these samples should', 'be collected in the morning (before noon), in order to control for diurnal variation. Please consult', 'the Central Laboratory Services Manual for details.', 'e.', 'The selection of exploratory bone and joint biomarkers to be tested will build on findings from', 'biomarker analyses in other emicizumab trials. Biomarkers that have been tested in these trials', 'include CTX-1, OPG, P1NP, and soluble RANK-L.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '165 / Protocol MO39129, Version 3']['Appendix 33', 'EmiPref Patient Preference Questionnaire', '(Paper Version, United Kingdom/English)', 'Instructions: You have been treated with intravenous (IV) Factor VIII or bypassing agent', '(your old hemophilia treatment) and prophylactic subcutaneous (SC) emicizumab (the new', 'study drug treatment). Please complete the following questions based on your experience', 'with these treatments.', 'There are no right or wrong answers and your responses will not influence your continued', 'participation in the study or treatment with emicizumab.', '1. Which of the treatments would you prefer to take as the treatment for your hemophilia?', '(Mark ONLY one response)', 'Prefer my old hemophilia treatment (IV)', 'Prefer the new study drug treatment (SC)', 'Have no preference', 'If you indicated a preference, please complete question 2.', 'If you did not have a preference, you do not need to complete questions 2.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '166 / Protocol MO39129, Version 3']['Appendix 3', 'EmiPref Patient Preference Questionnaire', '(cont.)', '2. Below are some factors that may have influenced your treatment preference. Please', 'indicate which factors had an influence on YOUR preference. Please indicate YES (this', 'influenced my preference) or NO (this did not influence my preference) for each item.', 'On those you said YES to, please rank the top 3 in order of importance (1 being the', '\"most important\" reason for your preference).', 'Yes', 'No', 'Importance', 'rank', 'Route of administration (IV or SC) was easier', 'Pain associated with treatment was less', 'Worry about finding a vein was less', 'Concern over port use/infection was less', 'Administration was easier', 'Able to keep treatment at room temperature', 'Time to administer treatment was shorter', 'The frequency of treatments was lower', 'Effect on other activities (work, school, sports,', 'social interactions) was less', 'Impact on family members and friends was less', 'Worries about having a bleed were less', 'Quality of life, in general, was better', 'It', 'was easier to take every dose my doctor', 'recommended', \"Made me feel more 'normal'\", '3. Please add any additional information about your experience with the study drug (SC', 'emicizumab).', 'Emicizumab - F. Hoffmann-La Roche Ltd', '167 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}